Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Innovating Sickle Cell Disease Treatment: From Non-Canonical Signaling and Immune Activation to Personalized Targeted Therapies

Objective

This project addresses the unmet clinical needs of sickle cell disease (SCD), the most common monogenic disorder worldwide, characterized by chronic inflammation, multi-organ involvement, and severely impaired erythropoiesis. SCD pathophysiology is driven by hemoglobin S polymerization, leading to vaso-occlusion (VOC) and acute chest syndrome (ACS), oxidative stress, and activation of innate immunity. Our multidisciplinary approach combines patient-driven biomarker studies, mechanistic investigations in human and mouse models, and exploration of innovative therapies. Preliminary data reveal that chronic bone marrow inflammation impairs hematopoietic stem/progenitor cell functions, alters erythroid differentiation, and increases myeloid bias, all contributing to poor transplant and gene therapy outcomes. Novel research in our group highlights the role of non-canonical histidine phosphorylation (NME1/NME2) in regulating BCL11A activity for fetal hemoglobin synthesis, and demonstrates that pharmacological targeting of these kinases safely induces HbF in human progenitors. We also uncover critical roles for mast cells and basophils, showing that their activation drives pain, vaso-occlusion, and neuroinflammation. Candidate drugs, including masitinib, luspatercept, and anti-inflammatory agents, are tested for their ability to improve hematopoiesis, reduce acute and chronic complications, and modulate the bone marrow niche. By integrating high-throughput sequencing, multi-omic profiling, and advanced mouse genetics, this project aims to identify new biomarkers and therapeutic strategies to personalize SCD care, improve gene therapy success, and rapidly translate findings from bench to bedside, offering hope for patients globally.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-ADG

See all projects funded under this call

Host institution

UNIVERSITE PARIS CITE
Net EU contribution
€ 1 460 375,00
Address
85 BD SAINT GERMAIN
75006 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (2)